Tuesday, Repare Therapeutics Inc (NASDAQ:RPTX) announced to regain global development and commercialization rights to camonsertib (RP-3500), following termination of its collaboration agreement with Roche Holdings AG (OTC:RHHBY).
Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.
Also Read: Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials.
Camonsertib is also part of Repare’s …
Leave a Reply